Drug-Induced QT interval prolongation: Regulatory perspectives and drug development

Annals of Medicine

Volumn 36, Issue SUPPL. 1, 2004, Pages 47-52

  Shah, Rashmi R ^a  

^a Medicines Hlthcare Prod R   (United Kingdom)

Author keywords

Bazett; Clinical trials; Dose schedules; Drug development; Fridericia; Metabolites; Pharmacogenetics; QT interval; Stereoselectivity; Torsade de pointes

Indexed keywords

ASTEMIZOLE; CISAPRIDE; FEXOFENADINE; LEVACETYLMETHADOL; NORASTEMIZOLE; PIMOZIDE; PRENYLAMINE; SERTINDOLE; TERFENADINE; TERIKALANT; TERODILINE; THIORIDAZINE;

CARDIOTOXICITY; CONCENTRATION RESPONSE; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ENZYME POLYMORPHISM; HEART DISEASE; HEREDITY; HUMAN; MEDICAL INFORMATION; MORBIDITY; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; TORSADE DES POINTES;

CLINICAL TRIALS; DRUG DESIGN; DRUG INCOMPATIBILITY; DRUG INTERACTIONS; DRUG THERAPY; HUMANS; LONG QT SYNDROME; RISK FACTORS; TORSADES DE POINTES;

EID: 2442667617     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.1080/17431380410032445     Document Type: Conference Paper

References (35)

1. Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001;104:569-80.
2. Shah RR. Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity. Fundam Clin Pharmacol 2002; 16:147-56.
3. Fung MC, Hsiao-hui Wu H, Kwong K, Hornbuckle K, Muniz E. Evaluation of the profile of patients with QTc prolongation in spontaneous adverse event reporting over the past three decades-1969-1.998. Pharmacoepidemiol and Drug Safety 2000;9 (Suppl 1):S24-5.
4. Salle P, Key JL, Bernasconi P, Quiret JC, Lombaert M. (Torsades de pointes. Apropos of 60 cases). [French]. Ann Cardiol Angeiol (Paris) 1985;34:381-8.
5. Milon D, Daubert JC, Saint-Marc C, Gouffault J. (Torsade de pointes. Apropos of 54 cases). [French]. Ann Fr Anesth Reanim 1982;1:513-20.
6. Shah RR. The significance of QT interval in drug development. Br J Clin Pharmacol 2002;54:188-202.
7. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993; 270:2590-7.
8. Rodriguez I, Kilborn MJ, Liu XK, Pezzullo JC, Woosley RL. Drug-induced QT prolongation in women during the menstrual cycle. JAMA 2001;285:1322-6.
9. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996;335:290-1.
10. Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001;96:1698-703.
11. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993;269: 1532-6.
12. Charbit B, Becquemont L, Lepere B, Peytavin G, Funck-Brentano C. Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine. Clin Pharmacol Ther 2002;72:514-23.
13. Roe CM, Odell KW, Henderson RR. Concomitant use of antipsychotics and drugs that may prolong the QT interval. J Clin Psychopharmacol 2003;23:197-200.
14. Curtis LH, Ostbye T, Sendersky V, Hutchison S, Allen LaPointe NM, Al-Khatib SM, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med 2003;114:135-41.
15. Shah RR. Pharmacogenetic aspects of drug-induced torsade de pointes: Potential tool for improving clinical drug development and prescribing. Drug Saf 2004:(in press).
16. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation 1999;99:529-33.
17. Shah RR. Withdrawal of terodiline: A tale of two toxicities. In: Mann RD, Andrews EB eds. Pharmacovigilance. London: John Wiley & Sons Ltd; 2002:135-54.
18. Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 2002;105: 1943-8.
19. Webster R, Allan G, Anto-Awuakye K, Harrison A, Kidd T, Leishman D, et al. Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog. Xenobiotica 2001;31:633-50.
20. Ben-David J, Zipes DP. Alpha-adrenoceptor stimulation and blockade modulates cesium-induced early afterdepolarizations and ventricular tachyarrhythmias in dogs. Circulation 1990;82:225-33.
21. Furushima H, Chinushi M, Washizuka T, Aizawa Y. Role of α1-blockade in congenital long QT syndrome-Investigation by exercise stress test. Jpn Circ J 2001;65:654-8.
22. Fulop G, Phillips RA, Shapiro AK, Gomes JA, Shapiro E, Nordlie JW. ECG changes during haloperidol and pimozide treatment of Tourette's disorder. Am J Psychiatry 1987;144: 673-5.
23. Volperian VR, Zhoti Z, Mohammad S, Hoon TJ, Studenik C, January CT. Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole. J Am Coll Cardiol 1996;28:1556-61.
24. Billon N, Funck-Brentano C, Cohen A, Chauvel C, Le Liboux A, Jaillon P. Influence of CYP2D6 genetic polymorphism on the pharmacokinetics and pharmacodynamic effects of terikalant, a new K+ channel blocker. Fundam Clin Pharmacol 1995;9:88.
25. Maginn M, Frederiksen K, Adamantidis MM, Bischoff U, Matz J. The effects of sertindole and its metabolites on cardiac ion channels and action potentials. J Physiol 2000;525:79P.
26. Hartigan-Go K, Bateman DN, Nyberg G, Martensson E, Thomas SH. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther 1996;60:543-53.
27. Thanaccody R, Daly AK, Thomas SH. Influence of CYP2D6 genotype on the QTc interval and plasma concentrations of thioridazine and its metabolites in psychiatric patients taking chronic therapy. Clin Pharmacol Ther 2003;73:77.
28. Hartigan-Go K, Bateman ND, Daly AK, Thomas SH. Stereoselective cardiotoxic effects of terodiline. Clin Pharmacol Ther 1996;60:89-98.
29. Bayer R, Schwarzmaler J, Pernice R. Basic mechanism underlying prenylamine-induced torsade de pointes: differences between prenylamine and fendiline due to basic actions of the isomers. Curr Med Res Opin 1988;11:254-72.
30. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58:32-45.
31. Sponer G. Prolongation of repolarization in pre-clinical investigations and phase I/II clinical trials: what should be done? Eur Heart J 2001;3 (Suppl K):K101-4.
32. De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf 2002;25:263-86.
33. Jaillon P, Morganroth J, Brumpt I, Talbot G. The Sparfloxacin Safety Group. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. J Antimicrob Chemotherap 1996;37 (Supp A):161-7.
34. Smalley W, Shatin D, Wysowski DK, Gurwitz J, Andrade SE, Goodman M, et al. Contraindicated use of cisapride: impact of Food and Drug Administration regulatory action. JAMA 2000;284:3036-9.
35. Krasucki C, McFarlane F. Electrocardiograms, high-dose antipsychotic treatment and College guidelines. Psychiatric Bull 1996;20:326-30.